Navigation Links
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
Date:11/2/2009

e and death," said Dr. Howard Kaufman of the Rush University Medical Center in Chicago, principal investigator of an ongoing Phase 3 OPTiM(TM) study with OncoVEX (GM-CSF) in Stage III and Stage IV melanoma. "The ability to simply administer the vaccine in the office setting represents a significant improvement in quality of life for patients with melanoma."

"We believe that OncoVEX (GM-CSF) is the most advanced clinical development program globally using viruses for cancer therapy, and we are committed to the further evaluation of OncoVEX (GM-CSF) for the treatment of metastatic melanoma and other solid tumors," said Robert Coffin, PhD, Founder & Chief Technology Officer of BioVex.

About the Phase 2 OncoVEX (GM-CSF) Study in Melanoma

The Phase 2 trial enrolled 50 patients with Stage IIIc (10 patients) and Stage IV melanoma (40 patients) who were treated with OncoVEX (GM-CSF) as a stand-alone therapy. The trial was designed to measure overall objective response, which is defined as a complete response, where disease is completely eliminated, or partial response, where there is a more than 30% reduction in disease burden. The vast majority of patients who entered the study had progressive disease after having failed conventional and experimental prior therapies. Fourteen objective systemic responses (28% objective response rate) were ultimately achieved, including on an extension protocol to which four patients were transferred having completed the main study, including 10 complete responses. Responses have been maintained for up to nearly four years so far. Responses were observed in patients with all stages of disease, including the complete resolution of un-injected visceral deposits.

About the OPTiM(TM) Phase 3 Study

BioVex has now begun a multi-national, randomized Phase 3 OPTiM Study to assess the efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to subcut
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
2. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
3. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
6. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
7. Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call
8. ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement
9. Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc.
10. Stryker Announces Change in Chairman of the Board of Directors
11. Cardica Announces Fiscal 2010 First Quarter Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
(Date:10/19/2014)... -- Shire plc (LSE: SHP, NASDAQ: SHPG ... (CFO), has notified the Board of Directors of his decision to ... opportunity as CFO of Severn Trent plc.  James will leave Shire ... a search for a new CFO immediately. Flemming Ornskov, ... and lead a high-quality finance team at Shire. We are very ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... GlySure Limited, developer of in-hospital continuous ... its $10.9 million Series C financing round. GlySure will ... approval in the United States and Europe. ... well as existing investors Amadeus Capital Partners, Chester Investments ...
... -- Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ... integrated pharmaceutical company engaged in the distribution of ... herbal cultivation and sales in China through its ... today announced the appointment of Mr. Kwong Chi ...
Cached Medicine Technology:GlySure Secures $10.9 Million in Series C Financing Round 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... 2014 It’s hard to imagine what it’s ... vulnerable children around the world, it’s a reality. And while ... children are forced to walk barefoot on rocky terrain or ... play with their friends. , Buckner International's Shoes ... Radio in October to encourage support for Air1 and ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... 2014 Recently, Top10BestSEOHosting.com has unveiled ... JustHost, GoDaddy and HostMonster are the best VPS ... Private Server) is the method of partitioning a ... which has the appearance and capabilities of running ... the site pays close attention to VPS products ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... A new approach of imaging discovered by scientists now detects even small smoking-related lung ... track deep into the smokers lungs and its movement - researchers at the University ... images of lungs soft tissues, when helium gas was inhaled prior taking images. ... ...
... anti-quota strike, setting the stage for a face-off with the ... the 19-day long protest can invite contempt proceedings. ... General Body Meetings of the medicos which saw sharp divisions ... has paralysed medical services in the capital., ,'The Youth ...
... incidence of HIV/AIDS is declining in the western Indian state ... , Karnataka and Andhra Pradesh because of the proactive measures ... in the country, especially in the north, it is rising, ... released Tuesday, said that overall two-thirds of the people living ...
... Court of India today asked the students to end their ... if they fail to do so contempt// action can be ... told that their protest had left "patients at the mercy ... are continuing with the strike. If they are over-reaching our ...
... Myanmar into India's northeast has led to a rise in ... says a United Nations study. ,"Drug trafficking across the ... Mizoram and Nagaland occurs with ease. Despite the existence of ... accessible to the local youths of these states," said a ...
... planning to study the effect of cervical cancer on the ... as the biggest study into the psychological and emotional effects ... will be instituted for duration of five years and will ... physical lives of couples. The researchers have said that they ...
Cached Medicine News:Health News:Helium And MRI Scanning Clearly Detects Smoker Lungs – Research Find 2Health News:Supreme Court Warns Medicos of Contempt Action 2Health News:Illegal Drug Trafficking Pose A Great Threat For HIV Epidemic In Northeast 2
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Malis CMC-III Generator provides both coagulation and cutting outputs....
Medicine Products: